MyFinsight
Home
Blog
About
Contact
Back
Cash Flow
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)
source: myfinsight.com
Download
Download image
Proceeds from issuance of
common stock
$35,098,813
Net cash provided by
financing activities
$34,624,149
Canceled cashflow
$474,664
Change in cash, cash
equivalents and restricted...
$31,867,423
Canceled cashflow
$2,756,726
Common stock issuance
costs
$474,664
Accrued expenses
$218,104
Prepaid expenses and
other current and...
-$181,777
Stock-based compensation
$101,068
Accounts payable
$32,525
Depreciation and
amortization
$5,428
Net cash used in
operating activities
-$2,756,726
Canceled cashflow
$538,902
Net loss
-$3,287,917
Foreign currency (gain)
loss
$7,711
Back